HUP0400987A2 - Vírusellenes szerek - Google Patents

Vírusellenes szerek

Info

Publication number
HUP0400987A2
HUP0400987A2 HU0400987A HUP0400987A HUP0400987A2 HU P0400987 A2 HUP0400987 A2 HU P0400987A2 HU 0400987 A HU0400987 A HU 0400987A HU P0400987 A HUP0400987 A HU P0400987A HU P0400987 A2 HUP0400987 A2 HU P0400987A2
Authority
HU
Hungary
Prior art keywords
nucleotide sequence
toxin
virus agent
encoding
stranded
Prior art date
Application number
HU0400987A
Other languages
English (en)
Inventor
Marina N. Papuashvili
Original Assignee
Technologie Integrale Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technologie Integrale Limited filed Critical Technologie Integrale Limited
Publication of HUP0400987A2 publication Critical patent/HUP0400987A2/hu
Publication of HUP0400987A3 publication Critical patent/HUP0400987A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány egyszálú RNS (+) vírusok ellen használható vírusellenesszerre vonatkozik, amely (A) az egyszálú vírus komplementer szálánakszintézisét irányító nukleotid szekvenciát, és (B) legalább a Shine-Dalgarno szekvenciát operábilisan egy toxint kódoló struktúrgénhezkapcsolva tartalmazó nukleotid szekvenciát tartalmaz, ahol a toxintkódoló nukleotid szekvencia antiszenz irányban helyezkedik el. Ó
HU0400987A 2001-05-04 2002-04-30 Anti-virus agent HUP0400987A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/848,269 US20030176372A1 (en) 2001-05-04 2001-05-04 Anti-virus agent
EP01110873A EP1254663B1 (en) 2001-05-04 2001-05-04 Anti-virus agent
PCT/EP2002/004774 WO2002089817A2 (en) 2001-05-04 2002-04-30 Anti-virus agent

Publications (2)

Publication Number Publication Date
HUP0400987A2 true HUP0400987A2 (hu) 2004-08-30
HUP0400987A3 HUP0400987A3 (en) 2004-10-28

Family

ID=46679311

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400987A HUP0400987A3 (en) 2001-05-04 2002-04-30 Anti-virus agent

Country Status (15)

Country Link
US (1) US20030176372A1 (hu)
EP (1) EP1254663B1 (hu)
JP (1) JP2005510455A (hu)
CN (1) CN1527716A (hu)
AT (1) ATE281838T1 (hu)
CA (1) CA2446204A1 (hu)
CZ (1) CZ20033288A3 (hu)
DE (1) DE60107052T2 (hu)
DK (1) DK1254663T3 (hu)
ES (1) ES2234730T3 (hu)
HU (1) HUP0400987A3 (hu)
IL (1) IL158739A0 (hu)
PL (1) PL367451A1 (hu)
PT (1) PT1254663E (hu)
WO (1) WO2002089817A2 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137415A1 (en) * 2007-04-20 2010-06-03 Takara Bio Inc. Vector for gene therapy
WO2017131079A1 (ja) * 2016-01-27 2017-08-03 国立大学法人北海道大学 ウイルスフリー植物体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973507A (en) * 1989-01-23 1990-11-27 Horian Richard C Thin wood laminate panel and method of fabrication
EP0479180A3 (en) * 1990-10-05 1992-08-26 Hoechst Aktiengesellschaft Virus resistant plants, method for their production

Also Published As

Publication number Publication date
ES2234730T3 (es) 2005-07-01
US20030176372A1 (en) 2003-09-18
CZ20033288A3 (cs) 2004-04-14
CN1527716A (zh) 2004-09-08
WO2002089817A3 (en) 2003-01-30
CA2446204A1 (en) 2002-11-14
WO2002089817A2 (en) 2002-11-14
DK1254663T3 (da) 2005-03-21
ATE281838T1 (de) 2004-11-15
PL367451A1 (en) 2005-02-21
EP1254663B1 (en) 2004-11-10
HUP0400987A3 (en) 2004-10-28
PT1254663E (pt) 2005-04-29
DE60107052D1 (de) 2004-12-16
DE60107052T2 (de) 2005-11-24
IL158739A0 (en) 2004-05-12
EP1254663A1 (en) 2002-11-06
JP2005510455A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
MY138477A (en) Modified fluorinated nucleoside analogues
HK1104302A1 (en) Short interfering rna, short hairpin rna and coding vectors thereof, related compositions and use thereof used for inhibiting influenza virus infection
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
WO2006047842A3 (en) Modified nucleosides for rna interference
AU2002252183A1 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ATE60800T1 (de) Klonierte dns-sequenzen, hybridisierbar mit genom-rns vom ''lymphadenopathy-associated virus (lav)''.
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
DK2354148T3 (da) Nukleosidanaloger og oligonukleotiderivate omfattende nukleotidanalog deraf
ATE495253T1 (de) Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer
MXPA01010392A (es) Produccion de vacunas de virus con arn de hebra negativa atenuados a partir de secuencias de nucleotidos clonadas.
FI922593A0 (fi) Inhibition av papillomavirus med çantisenseç-oligonukleotider.
HUP0400987A2 (hu) Vírusellenes szerek
ATE294866T1 (de) Zellen, die virus-resistent und von viren infizierbar sind
HUP0302233A2 (hu) Virális betegségek kezelésére IL-18-cal és IL-18 kombinációkkal
ATE532792T1 (de) Künstliches cpg einzelstrang oligodeoxynukleotid und dessen antivirale anwendungen
EA200301089A1 (ru) Противовирусный агент
DE60035680D1 (de) Komplette gensequenz des esel-leukozyten-impfstoffstammes des equinen infektiösen anemievirus und ihre anwendung
DE60140552D1 (de) Transglutaminase genprodukte
WO2002068582A3 (en) Phosphorothioate (p=s) oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof
DK0611373T3 (da) Oligo-2-desoxynukleotider og deres anvendelse som lægemidler med antiviral virkning.
RU2001123408A (ru) Набор олигонуклеотидов-праймеров для идентификации РНК вируса Крымской-Конго геморрагической лихорадки
CY1114414T1 (el) Διαδικασιες για πακεταρισμα ολιγονουκλεοτιδιων σε ιομορφα σωματιδια rna βακτηριοφαγων

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees